{
    "body": "List sodium glucose co-transporter-2 (SGLT2) inhibitors that have been FDA approved for type 2 diabetes mellitus treatment.", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25712444", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22632452", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25488697", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22433611", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24741548", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24455799", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25414933", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24585202", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25255411", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24059302", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25688893", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25598831", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24998153", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23194084", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24040872", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24025022", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22583331", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19243283", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24633706", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24950857", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24705156", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25059406", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23729000", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22548646"
    ], 
    "ideal_answer": [
        "Canagliflozin, along with dapagliflozin and empagliflozin, are SGLT2 inhibitors approved by the US FDA for use in the treatment of type 2 diabetes."
    ], 
    "exact_answer": [
        [
            "Dapagliflozin"
        ], 
        [
            "Empagliflozin"
        ], 
        [
            "Canagliflozin"
        ]
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003924", 
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014486", 
        "http://www.uniprot.org/uniprot/SC5A2_MOUSE", 
        "http://www.disease-ontology.org/api/metadata/DOID:9352", 
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017277", 
        "http://www.uniprot.org/uniprot/SC5A2_RAT", 
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051297", 
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051273"
    ], 
    "type": "list", 
    "id": "571e189dbb137a4b0c000003", 
    "snippets": [
        {
            "offsetInBeginSection": 151, 
            "offsetInEndSection": 319, 
            "text": "Canagliflozin was the first SGLT2 inhibitor to be approved by the US FDA for use in the treatment of type 2 diabetes, and recently dapagliflozin has also been approved.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24998153", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 11, 
            "offsetInEndSection": 257, 
            "text": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 656, 
            "offsetInEndSection": 802, 
            "text": " Empagliflozin is a new once-daily oral SGLT2 inhibitor with a mechanism of action that is independent of \u03b2-cell function and the insulin pathway.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 159, 
            "text": "Sodium-glucose cotransporter type 2 (SGLT2) inhibitors such as canagliflozin and dapagliflozin have been approved for the treatment of type 2 diabetes mellitus", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25688893", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 245, 
            "text": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 215, 
            "offsetInEndSection": 494, 
            "text": "The present study emphasizes the molecular interactions between a new Food and Drug Administration (FDA) approved antidiabetic drug 'Invokana' (chemically known as Canagliflozin) with AChE and SGLT2 to establish a link between the treatment of T2DM and Alzheimer's Disease (AD). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24059302", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 195, 
            "text": "Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24059302", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 142, 
            "offsetInEndSection": 296, 
            "text": "This analysis assessed the effects of the SGLT2 inhibitor, canagliflozin, on model-based measures of beta cell function in patients with type 2 diabetes. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24585202", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 306, 
            "text": " Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) promote the excretion of glucose to reduce glycated hemoglobin (HbA1c) levels. Canagliflozin was the first SGLT2 inhibitor to be approved by the US FDA for use in the treatment of type 2 diabetes, and recently dapagliflozin has also been approved.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24998153", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 47, 
            "offsetInEndSection": 247, 
            "text": "a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 247, 
            "text": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712444", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 99, 
            "text": "Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24025022", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 267, 
            "text": "Canagliflozin (Invokana\u2122), an oral selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, is under global development with Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, for the treatment of type 2 diabetes mellitus.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729000", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 196, 
            "text": "Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24059302", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 138, 
            "offsetInEndSection": 306, 
            "text": "Canagliflozin was the first SGLT2 inhibitor to be approved by the US FDA for use in the treatment of type 2 diabetes, and recently dapagliflozin has also been approved.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24998153", 
            "endSection": "abstract"
        }
    ]
}